Using a connected scale to monitor weight and vitals during lymphoma and myeloma treatment
Official title: Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Run by Assistance Publique - Hôpitaux de Paris · NCT06133426 · Data updated 2026-11-12
This project will test whether daily use of a connected scale to track weight and heart rate at home can help people with lymphoma or multiple myeloma who are receiving chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | September 4, 2025 |
| Main results expected | May 2026 |
| Study ends | May 2026 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT06133426 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with aggressive non-Hodgkin lymphoma or multiple myeloma who are starting or within two cycles of systemic chemotherapy or require intensification/autograft, can use the device, speak French, be contacted by phone, return home after initial hospitalization, and provide informed consent are ideal candidates.
✕Probably not a fit
Patients with estimated life expectancy under three months, moderate to severe cognitive impairment, inability to use the device, a pacemaker, pregnancy, or currently enrolled in another interventional research project are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Thirty adult patients with aggressive non-Hodgkin lymphoma or multiple myeloma receiving systemic chemotherapy (or within the first two cycles or undergoing therapeutic intensification/autograft) will use a Withings Body Comp Pro connected scale for about seven weeks. Participants will be asked to weigh themselves once daily at a consistent time, with weight and available vital data transmitted to a remote monitoring platform accessible to the clinical team. The platform will generate alerts for abnormal changes in predefined clinical parameters to prompt earlier clinical intervention. At study end, investigators will review how patients experienced the tool and analyze the healthcare actions triggered by the alerts.
Why it matters
Potential benefit: If successful, this approach could enable earlier detection of clinical deterioration and faster medical response, potentially reducing complications and urgent care needs.
How similar studies have gone: Remote monitoring interventions in oncology and chronic disease have shown promise for early detection of deterioration, but use of a connected scale specifically in hematology patients is relatively novel and not widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 and over (male or female) * Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma * Patient who can be contacted by telephone during their participation in the research * Patient able to return home at the end of their initial hospitalization * Patient affiliated to social security * Patient able to read and speak French * Patient having signed free, informed and written consent Exclusion Criteria: * Patient with an estimated life expectancy \< 3 months * Patient with moderate to severe cognitive impairment (assessed by MMSE \< 20) * Patient with a psychiatric or physical disability that does not allow the use of the device * Patient with a pacemaker * Patient participating in another intervention research project * Pregnant patient * Patient deprived of liberty * Patient under legal protection (guardianship or curatorship)
Where it's running
-
Cochin Hospital
Paris, France Recruiting
Study contacts
- Study coordinator: Rudy BIRSEN, Dr
- Email: rudy.birsen@aphp.fr
- Phone: 01.58.41.42.90
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JMBI-001 in MYC-Positive Advanced Cancers
This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.
-
BCD-248 plus daratumumab in relapsed or refractory multiple myeloma
This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.
-
UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas
A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.
-
Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma
This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.
-
Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma
This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.
-
Infectious complications in blood cancer patients treated with bispecific antibodies
This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.